Anzeige
Erschienen in:
01.03.2008
The Changing Use of Palliative Chemotherapy for Recurrent Esophagogastric Cancer: A Single Center Retrospective 15-Year Review
Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1-4/2008
Einloggen, um Zugang zu erhaltenAbstract
Background
Palliative chemotherapy is often recommended in the treatment of recurrent esophagogastric (EG) cancer with limited evidence of its benefit. This study aims to define the current practice and benefit of this treatment.
Methods
Retrospective analysis of patients who developed EG cancer recurrence between 1991 and 2006 following surgery with curative intent.
Results
There were 336 recurrences. Median time to disease recurrence was 13.4 months (range 1.3–118). Survival after recurrence ranged from 0–93.2 months (six patients are currently alive). A significant increase in the use of chemotherapy was observed rising from 10% prior to 1999 (n = 100) to 23% (n = 236) after 1999. The median survival for patients receiving chemotherapy (n = 64) was 10.6 months (range 1.5–75.7), patients undergoing nonchemotherapy palliative intervention (n = 142) median survival was 2.85 months (range 0–93.2), and for patients having no active intervention (n = 130), median survival was 1.3 months (range 0–16.2). Median duration of chemotherapy was 3.1 months (range 0.5–9.2). Median survival for these patients after chemotherapy treatment was 6.6 months (range 0.4–73.5). Twenty-eight patients (44%) experienced side effects of chemotherapy. Ten cases required treatment to be modified or stopped and two patients died during chemotherapy.
Conclusion
There has been a significant increase in the use of palliative chemotherapy for recurrent EG cancer. While survival appears improved, a substantial proportion of this time was spent receiving chemotherapy with many patients experiencing significant comorbidity. Further studies assessing both quality and quantity of life are required to fully evaluate the use of palliative chemotherapy and to identify patients most likely to benefit.